Onco Actu du 21 mai 2015

	1. Biologie
Novel Microfluidic Device May Shed Light on Why Cancer Cells Metastasize [GEN] In a test using aggressive metastatic breast cancer cells, the researchers were able to sort the cells based on their motion, collect the sorted cells and send them through the device again.
Device smushes cancer to see if it's squishy [Futurity] In addition to evaluating the device’s role in a clinical setting, there is also increased interest on a more fundamental level: understanding how different types of tumors are related to their mechanical properties, an emerging research field that is part of a growing interest in physical oncology—the study of the physics of cancer.
	2. Etiologie
Links between hay fever, asthma and prostate cancer inconclusive [NHS Choices] The possibility that inflammation, or the immune system more generally, could be associated with risk of prostate cancer is plausible, but this study tells us little about how different immune profiles could influence cancer risk.
	3. Prévention
Well: How a Childhood Vaccine Reduces Risk of a Cancer [NY Times] Young children are routinely vaccinated against Haemophilus influenza type B, or HiB, a bacterium that can cause meningitis and other serious problems. But the HiB vaccine has an added benefit: It reduces the risk for acute lymphoblastic leukemia, or ALL, the most common childhood cancer, and now scientists know why.
	3.1 Tabac
MPs took tobacco firms' gifts before packaging vote [The Telegraph] MPs and peers accepted gifts from the tobacco industry, such as tickets to the men’s final at Wimbledon and the opera at Glyndebourne, before voting against plain packaging, an investigation has found.
	3.5 Prévention - UV
Don't Fry Day Reminds Us To Stay Safe In The Sun [Dr Len] When I reflect back on what caused my skin cancers and my age spots that's what I can say. But in fact we couldn't do it. We didn't have sunscreen, we didn't know about the harms of the sun, maybe we wore a baseball cap occasionally, and we certainly didn't have the comfortable, good-looking outdoor clothing that we have today.
	4.1 Dép., diag. & prono. - Prostate
UCSF-led Study Shows Oncotype DX® and MRI May Provide Independent Information in Favorable Risk Prostate Cancer [Genomic Health] Presentation at American Urological Association 2015 Annual Meeting Reconfirms Oncotype DX Genomic Prostate Score as Independent Predictor of Adverse Pathology.
	5. Traitements
Combining targeted cancer drugs is best when used to the max [The Institute of Cancer Research] The findings have important implications for how clinical trials combining MEK and AKT inhibitors are conducted, and questions drug schedules recommended by continuous dosing which may only partially inhibit MEK and AKT signalling.
Study Finds Biomarker May Boost Ovarian Cancer Chemotherapy Response [MD Anderson Cancer Center] A study at The University of Texas MD Anderson Cancer Center has identified miR-506, a non-coding “micro” RNA molecule, as a likely robust clinical marker for epithelial ovarian cancer chemotherapy, and as a potential therapy due to its ability to sensitize cancer cells to chemotherapy.
	5.12 Immunothérapies
Emerging Approaches to Cancer Immunotherapy [The New York Academy of Sciences] Areas of investigation such as checkpoint blockade inhibitors, advanced tumor vaccination studies, and adoptive T-cell therapies are changing the face of cancer treatment. This symposium will bring together leading experts in immunotherapy and immunology to discuss these emerging approaches, along with the challenges and opportunities faced in this evolving field.
	5.2 Pharma
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors [Novartis] Full results from the RADIANT-4 study will be submitted to a major medical meeting.
Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed $1 Billion in Revenue [Johnson & Johnson] Janssen is also announcing today that it plans to submit a Biologic Licensing Application to the FDA and a Marketing Authorization Application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase 2 data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.
J&J says will submit 10 medicines to regulators by 2019 [Reuters] J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United States and Europe this year based on mid-stage clinical data. Wells Fargo analyst Larry Biegelsen forecast daratumumab sales reaching $1.3 billion by 2019.
	5.2.2 Pharma - Fusions & Acquisitions
Should Pfizer snap up GSK? Well, a megadeal could speed up a split [FiercePharma] Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline? That's Deutsche Bank's suggestion, anyway.
	5.5.1 ASCO (général)
Industry awaits key immunotherapy results at ASCO [Pharmafile] This year’s American Society of Clinical Oncology (ASCO) conference has a strong focus on immunotherapy, as pharma ramps up its efforts in this exciting treatment area.
	5.5.1.1 ASCO (général) - Industriels
AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma [Aveo] The Company previously reported interim median progression free survival (PFS) results of 8.4 months among the 163 patients enrolled in Study 902. Final results now show a median PFS in this setting of 11.0 months and median overall survival (OS) of 21.6 months, demonstrating the efficacy of tivozanib in a VEGF treatment refractory population.
OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting [OncoGenex] Survival Benefit Seen with Custirsen and Apatorsen in Patients with Greatest Therapeutic Need.
	5.5.10 ASCO (hémato)
ERYTECH announces oral presentations of GRASPA® Phase III results at ASCO and EHA annual meetings [Erytech Pharma] The data to be presented will include full Phase III results of the GRASPIVOTALL trial, a controlled, multicenter trial comparing GRASPA® (development name: ERY001) to native L-asparaginase (L-ASP) in children and adults suffering from relapsed or refractory ALL.
	6. Lutte contre les cancers
Many hands make light work – the evolution of clinical trials [Cancer Research UK] Today is International Clinical Trials Day, which aims to raise awareness of clinical trials – and their importance in modern medicine. It falls on 20th May because that’s the date of the first recorded clinical trial, conducted in 1747 by a Scottish naval surgeon called James Lind.
	6.1 Observation
Cancer waiting time targets – simply not good enough [Cancer Research UK] But this isn’t really about NHS targets. It’s about patients being let down. Over the last three months, nearly 6,000 people have had to wait longer than they should for cancer treatment.
NHS fails 'thousands' cancer patients [BBC News] Sara Hiom, the director of early diagnosis at Cancer Research UK, said: "This is the worst result since records began, in 2009.
NHS cancer care faces fresh scrutiny after hospitals miss key targets [The Guardian] Official figures released on Wednesday by NHS England show that up to a quarter of patients with three common types of the disease did not receive their first treatment within the required 62 days, despite having been urgently referred for it by their GP.
	6.10 Politiques
Morocco joins the International Agency for Research on Cancer [ecancer - News] Morocco has become the 25th country to join IARC and is, notably, the first IARC Participating State from the African continent.
	6.3 Associations
Bogus Cancer Charities Are Harmful To Patients: How To Give Wisely [Forbes] I admit a personal soft spot for (real) breast cancer charities. So I’ll focus on crimes allegedly perpetrated by the Breast Cancer Society (BCS).
	6.6 Publications
Open-access publisher sacks 31 editors amid fierce row over independence [Science] Frontiers, based in Lausanne, Switzerland, removed 31 editors of Frontiers in Medicine and Frontiers in Cardiovascular Medicine on 7 May after the editors complained that company staff were interfering with editorial decisions and violating core principles of medical publishing.
	6.8 Communication
Dana-Farber/Brigham and Women's Cancer Center launches online resource for precision cancer medicine [Dana-Farber Cancer Institute] The new website includes various sections that are easy to navigate and explore.
NanoKnife for pancreatic cancer: Why a disputed news release reflects important truths about health care news [HealthNewsReview] To the broader public, it may seem as if health news coming out of a university is about the dispassionate communication of scientific truth. But as these examples may illustrate, the way that research gets communicated may also be impacted by egos, money, and control struggles — just like with any other human endeavor.
	6.9 Controverses
Opinion: Public Data, Private Concerns [The Scientist] Disregarding research participants’ concerns about data privacy and data security could irreparably damage public trust in science, and ultimately hinder progress in any field that requires the participation of people.